Search results for "MC"

showing 10 items of 2122 documents

Clinical and neuroimaging findings in 33 patients with MCAP syndrome: A survey to evaluate relevant endpoints for future clinical trials

2021

Megalencephaly-CApillary malformation-Polymicrogyria (MCAP) syndrome results from somatic mosaic gain-of-function variants in PIK3CA. Main features are macrocephaly, somatic overgrowth, cutaneous vascular malformations, connective tissue dysplasia, neurodevelopmental delay, and brain anomalies. The objectives of this study were to describe the clinical and radiological features of MCAP, to suggest relevant clinical endpoints applicable in future trials of targeted drug therapy. Based on a French collaboration, we collected clinical features of 33 patients (21 females, 12 males, median age of 9.9 years) with MCAP carrying mosaic PIK3CA pathogenic variants. MRI images were reviewed for 21 pat…

AdultMale0301 basic medicinePediatricsmedicine.medical_specialtyCutis marmorataAdolescentClass I Phosphatidylinositol 3-KinasesNeuroimagingContext (language use)Skin Diseases Vascular030105 genetics & heredityCohort StudiesYoung Adult03 medical and health sciencesGeneticsPolymicrogyriamedicineHumansPROSAbnormalities MultipleTelangiectasisMegalencephalyChildMCAP syndromeGenetics (clinical)Chiari malformationClinical Trials as Topicbusiness.industryMacrocephalyPIK3CAmedicine.diseaseMagnetic Resonance ImagingMegalencephaly3. Good healthClinical trial030104 developmental biologyChild PreschoolPostnatal macrocephalyFemalemedicine.symptombusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyForecastingVentriculomegalyClinical Genetics
researchProduct

A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus

2014

Contains fulltext : 137763.pdf (Publisher’s version ) (Open Access) Recent genome-wide association studies (GWAS) of Hodgkin lymphoma (HL) have identified associations with genetic variation at both HLA and non-HLA loci; however, much of heritable HL susceptibility remains unexplained. Here we perform a meta-analysis of three HL GWAS totaling 1,816 cases and 7,877 controls followed by replication in an independent set of 1,281 cases and 3,218 controls to find novel risk loci. We identify a novel variant at 19p13.3 associated with HL (rs1860661; odds ratio (OR)=0.81, 95% confidence interval (95% CI)=0.76-0.86, Pcombined=3.5 x 10(-10)), located in intron 2 of TCF3 (also known as E2A), a regul…

AdultMaleAdolescent[SDV]Life Sciences [q-bio]TRANSCRIPTION FACTOR E2AGENETIC-ASSOCIATIONGeneral Physics and AstronomyLocus (genetics)Genome-wide association studyHuman leukocyte antigenBiologyGeneral Biochemistry Genetics and Molecular BiologyArticleDISEASEYoung AdultBasic Helix-Loop-Helix Transcription FactorsHumansTOOLGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONEPSTEIN-BARR-VIRUSGenetic associationAgedGeneticsAged 80 and overRISKMultidisciplinaryCELL-TYPECase-control studyGenetic VariationGeneral ChemistryOdds ratioGenomicsMiddle AgedALLELESHodgkin DiseaseCANCERMalaltia de HodgkinHodgkin lymphoma (HL)GenòmicaGenetic epidemiologyCase-Control StudiesUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]Hodgkin's diseaseChromosomes Human Pair 19Genome-Wide Association Study
researchProduct

Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global Burden of Disease Study …

2022

Background: The health risks associated with moderate alcohol consumption continue to be debated. Small amounts of alcohol might lower the risk of some health outcomes but increase the risk of others, suggesting that the overall risk depends, in part, on background disease rates, which vary by region, age, sex, and year. Methods: For this analysis, we constructed burden-weighted dose-response relative risk curves across 22 health outcomes to estimate the theoretical minimum risk exposure level (TMREL) and non-drinker equivalence (NDE), the consumption level at which the health risk is equivalent to that of a non-drinker, using disease rates from the Global Burden of Diseases, Injuries, and …

AdultMaleAlcohol DrinkingCONTROL POLICIESadult; Alcohol Drinking; Child Preschool; Female; Geography; Global Burden of Disease; Global Health; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Risk FactorsNDASALL-CAUSEGUIDELINESGlobal HealthGBD 2020 Alcohol CollaboratorsGlobal Burden of DiseaseCOST-EFFECTIVENESSMedicine General & InternalDRINKINGSDG 3 - Good Health and Well-beingRA0421Risk FactorsGeneral & Internal MedicineQuality-Adjusted Life YearRA0421 Public health. Hygiene. Preventive MedicineDRINKERSHumansChildPreschool11 Medical and Health SciencesMETAANALYSISMCCScience & Technologyglobal burden of diseaseGeographyRisk FactoradultGeneral MedicineMiddle AgedCANCERalcohol drinkingACChild Preschool3121 General medicine internal medicine and other clinical medicineFemaleQuality-Adjusted Life YearsREDUCED MORTALITYLife Sciences & Biomedicinealcohol drinking; global burden of disease; adultHuman
researchProduct

Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer

2005

Abstract BACKGROUND AND AIMS: oxaliplatin in combination with folinic acid (FA) and infusional 5-fluorouracil (5-FU) has shown significant anti-tumor activity in gastric cancer patients (FOLFOX). Previous studies have shown that gemcitabine (GEM), a new fluorinated anti-metabolite, enhances the individual anti-tumor activity of either 5-FU or oxaliplatin. We have therefore designed a multi-center phase II trial in order to test a novel GEM+FOLFOX-4 regimen in patients with metastatic gastric cancer. METHODS: we enrolled 36 patients, 28 males and 8 females, with an average age of 64.4 years (range 37-78), who received bi-weekly treatment with GEM (1,000 mg/m2 on day 1), levo-FA (100 mg/m2 on…

AdultMaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsGastrointestinal Diseasesmedicine.drug_classfolinic acidmedicine.medical_treatmentLeucovorinAdenocarcinomaToxicologyDeoxycytidineAntimetaboliteGastroenterologyFolinic acidFOLFOXStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans5-fluorouracilPharmacology (medical)Infusions IntravenousAgedNeoplasm StagingPharmacologyChemotherapybusiness.industrygastric canceroxaliplatingemcitabineMiddle AgedHematologic DiseasesGemcitabineSurgeryOxaliplatinSurvival RateRegimenOncologyFluorouracilFemaleNeurotoxicity SyndromesFluorouracilbusinessmedicine.drugCancer Chemotherapy and Pharmacology
researchProduct

Oxidative Stress Parameters in Saliva and Its Association with Periodontal Disease and Types of Bacteria

2015

Objective. To determine the association between oxidative stress parameters with periodontal disease, bleeding, and the presence of different periodontal bacteria.Methods. A cross-sectional study in a sample of eighty-six patients, divided into three groups depending on their periodontal status. Thirty-three with chronic periodontitis, sixteen with gingivitis, and thirty-seven with periodontal healthy as control. Oxidative stress biomarkers (8-OHdG and MDA), total antioxidant capacity (TAOC), and the activity of two antioxidant enzymes (GPx and SOD) were determined in saliva. Subgingival plaque samples were obtained from the deepest periodontal pocket and PCR was used to determine the prese…

AdultMaleArticle SubjectGingival and periodontal pocketClinical BiochemistryMicrobiologyGingivitisMalondialdehydeGeneticsmedicineTannerella forsythiaHumansPeriodontitisSalivaMolecular BiologyPorphyromonas gingivalisPeriodontitislcsh:R5-920Glutathione Peroxidasebiologybusiness.industrySuperoxide DismutaseMicrobiotaBiochemistry (medical)Aggregatibacter actinomycetemcomitansDeoxyguanosineTreponema denticolaGeneral Medicinemedicine.diseasebiology.organism_classificationChronic periodontitisOxidative Stress8-Hydroxy-2'-DeoxyguanosineCase-Control StudiesFemalemedicine.symptomlcsh:Medicine (General)businessBiomarkersResearch ArticleDisease Markers
researchProduct

The Influence of Chitosan on the Oral Bioavailability of Acyclovir-a Comparative Bioavailability Study in Humans

2015

Purpose The effects of chitosan hydrochloride on the oral absorption of acyclovir in humans were studied to confirm the absorption enhancing effects reported for in vitro and rat studies, respectively. Methods A controlled, open-label, randomized, 3-phase study was conducted in 12 healthy human volunteers. Zovirax 200 mg dispersible tablets co-administered with doses of 400 and 1000 mg chitosan HCl were compared with Zovirax only. Results The expected increased absorption of acyclovir was not observed. On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and …

AdultMaleBioavailability StudyAcyclovirAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyAbsorption (skin)PharmacologyAntiviral Agents030226 pharmacology & pharmacyHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Chitosan03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsbiopharmaceutics classification systemHumansMedicinePharmacology (medical)Chromatography High Pressure LiquidPharmacologyChitosanDrug Carriersbusiness.industryOrganic Chemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverHealthy Volunteers3. Good healthBioavailabilitychemistryexcipient interactionsData Interpretation StatisticalMolecular MedicineFemaleChitosan hydrochloridebioavailability0210 nano-technologybusinesspharmacokineticsResearch PaperBiotechnologyBiological availabilityPharmaceutical Research
researchProduct

Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of th…

2017

Abstract Introduction The epidemiology of squamous cell oral cavity and pharyngeal cancers (OCPC) has changed rapidly during the last years, possibly due to an increase of human papilloma virus (HPV) positive tumors and successes in tobacco prevention. Here, we compare incidence and survival of OCPC by HPV-relation of the site in Germany and the United States (US). Materials and methods Age-standardized and age-specific incidence and 5-year relative survival was estimated using data from population-based cancer registries in Germany and the US Surveillance Epidemiology and End Results (SEER) 13 database. Incidence was estimated for each year between 1999 and 2013. Relative survival for 2002…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentPopulationHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciencesYoung AdultAll institutes and research themes of the Radboud University Medical Center0302 clinical medicinePharyngeal cancerGermanyEpidemiologySurveillance Epidemiology and End ResultsMedicineHumans030212 general & internal medicineeducationAgededucation.field_of_studyRelative survivalbusiness.industryIncidence (epidemiology)IncidencePharynxPapillomavirus InfectionsCancerPharyngeal NeoplasmsMiddle Agedmedicine.diseaseSurvival AnalysisUnited StatesSurgeryTumor Virus Infectionsmedicine.anatomical_structureOncology030220 oncology & carcinogenesisFemaleMouth NeoplasmsOral SurgerybusinessDemography
researchProduct

The EORTC module for quality of life in patients with thyroid cancer: phase III

2017

The purpose of the study was to pilot-test a questionnaire measuring health-related quality of life (QoL) in thyroid cancer patients to be used with the European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire EORTC QLQ-C30. A provisional questionnaire with 47 items was administered to patients treated for thyroid cancer within the last 2 years. Patients were interviewed about time and help needed to complete the questionnaire, and whether they found the items understandable, confusing or annoying. Items were kept in the questionnaire if they fulfilled pre-defined criteria: relevant to the patients, easy to understand, not confusing, few missing values, neither …

AdultMaleCancer Researchmedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismPilot ProjectsIodine Radioisotopes03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeInternal medicineSurveys and QuestionnairesMedicineHumansIn patientThyroid NeoplasmsThyroid cancerProtein Kinase InhibitorsAgedAged 80 and overbusiness.industryCancerMiddle Agedmedicine.diseasehumanitiesSurgeryOncology030220 oncology & carcinogenesisQuality of LifeFemalebusinessRare cancers Radboud Institute for Health Sciences [Radboudumc 9]
researchProduct

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multic…

2006

BACKGROUND. To date, the standard treatment for patients who have carcinoma of unknown primary site has not been established. METHODS. In this randomized Phase II study, 66 previously untreated patients (33 patients per arm) with carcinomas of unknown primary site received cisplatin (35 mg/m2) and gemcitabine (1000 mg/m2) with either paclitaxel (70 mg/m2) or vinorelbine (25 mg/m2), and all drugs were administered intravenously on Days 1 and 8 of a 21-day cycle. Twenty-nine patients (44%) presented with ≥2 involved sites. The pathologic diagnosis was mainly adenocarcinoma (48 patients; 72.7%) and squamous carcinoma (7 patients; 10.6%). RESULTS. In the first arm, 16 patients (48.5%) experienc…

AdultMaleCancer Researchmedicine.medical_specialtyPaclitaxelmedicine.medical_treatmentPhases of clinical researchVinorelbineVinblastineGastroenterologyDeoxycytidineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedChemotherapybusiness.industryStandard treatmentCarcinomaVinorelbineMiddle AgedGemcitabineGemcitabineSquamous carcinomaSurgeryRegimenOncologyTolerabilityItalyInjections IntravenousNeoplasms Unknown PrimaryFemaleCisplatinbusinessmedicine.drugCancer
researchProduct

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

2004

Contains fulltext : 57114.pdf (Publisher’s version ) (Closed access) Chimeric monoclonal antibody G250 (WX-G250) binds to a cell surface antigen found on >90% of renal cell carcinoma (RCC). A multicentre phase II study was performed to evaluate the safety and efficacy of WX-G250 in metastatic RCC (mRCC) patients. In all, 36 patients with mRCC were included. WX-G250 was given weekly by intravenous infusion for 12 weeks. Patients with stable disease (SD) or response were eligible to receive additional treatment for 8 weeks. None of the 36 enrolled patients experienced any drug-related grade III or IV toxicity. Only three patients had grade II toxicity possibly related to the study medication.…

AdultMaleCancer Researchmedicine.medical_specialtyrenal cell carcinomaRecombinant Fusion ProteinsPhases of clinical researchAntineoplastic AgentsGastroenterologyClinicalMonoclonal antibody G250Renal cell carcinomaInternal medicinemedicineCarcinomaHumansProspective StudiesCarcinoma Renal CellAgedbusiness.industryGirentuximabAntibodies MonoclonalImmunotherapy gene therapy and transplantation [UMCN 1.4]CA-IXMiddle Agedmedicine.diseaseKidney NeoplasmsSurgeryClinical trialTreatment OutcomeOncologymonoclonal antibodyAntigens SurfaceFemaleimmunotherapybusinessWX-G250Progressive diseasemedicine.drugKidney disease
researchProduct